Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2) and (#3 or #4)
Latest & greatest articles for breast cancer
The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on breast cancer or other clinical topics then use Trip today.
This page lists the very latest high quality evidence on breast cancer and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.
What is Trip?
Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.
Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.
As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.
For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via email@example.com
Metastatic BreastCancer Summary Metastatic breastcancerBreastcancer is the most common cancer diagnosed in Australia. Approximately 5% of patients diagnosed with breastcancer in Australia have metastatic disease at initial breastcancer diagnosis (NCCI, Cancer Australia), and some patients who have early breastcancer at diagnosis will have a recurrence that is metastatic. However exact statistics on patients with metastatic breastcancer in Australia are not currently available (...) . For patients with metastatic breastcancer at diagnosis in Australia, 5-year relative survival is low at 32%, compared with over 95% for patients with early breastcancer. While many patients with metastatic breastcancer are living longer, current treatments for metastatic breastcancer are generally not curative. The main treatment goals for metastatic breastcancer are to effectively manage symptoms and optimise quality of life, as well as to prolong survival. There can be emotional, physical
Baseline Staging Imaging for Distant Metastasis in Women with Stage I, II, and III BreastCancer Guideline 1-14 Version 3 A Quality Initiative of the Program in Evidence-Based Care (PEBC), Cancer Care Ontario (CCO) Baseline Staging Imaging for Distant Metastasis in Women with Stage I, II, and III BreastCancer A. Arnaout, N. Varela, M. Allarakhia, L. Grimard, A. Hey, J. Lau, L. Thain, A. Eisen, and the Staging in Early Stage BreastCancer Advisory Committee 1 Report Date: October 7, 2019 (...) (Vancouver Style): Arnaout A, Varela NP, Allarakhia M, Grimard L, Hey A, et al. Baseline staging imaging for distant metastasis in women with stage I, II, and III breastcancer. Toronto (ON): Cancer Care Ontario; 2019 October 7. Program in Evidence- Based Care Guideline No.: 1-14 Version 3. Copyright This report is copyrighted by Cancer Care Ontario; the report and the illustrations herein may not be reproduced without the express written permission of Cancer Care Ontario. Cancer Care Ontario reserves
Triptorelin acetate (Decapeptyl) - breastcancer 1 Published 7 October 2019 1 SMC2186 triptorelin sustained-release 3mg powder for suspension for injection (Decapeptyl SR®) Ipsen Ltd. 06 September 2019 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises NHS Boards and Area Drug and Therapeutic Committees (ADTCs) on its use in NHSScotland. The advice is summarised as follows: ADVICE: following a full submission triptorelin (Decapeptyl SR ® (...) ) is accepted for use within NHSScotland. Indication under review: As adjuvant treatment in combination with tamoxifen or an aromatase inhibitor, of endocrine responsive early stage breastcancer in women at high risk of recurrence who are confirmed as premenopausal after completion of chemotherapy. In premenopausal women with early breastcancer at high risk of recurrence, ovarian suppression (provided by triptorelin, oophorectomy or radiation ablation) plus an aromatase inhibitor increased disease free
Pertuzumab (Perjeta) - HER2-positive early breastcancer 1 Published 07 October 2019 1 SMC2197 pertuzumab 420mg concentrate solution for infusion (Perjeta®) Roche Products Ltd 06 September 2019 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises NHS Boards and Area Drug and Therapeutic Committees (ADTCs) on its use in NHSScotland. The advice is summarised as follows: ADVICE: following a full submission considered under the orphan equivalent (...) process pertuzumab (Perjeta®) is not recommended for use within NHSScotland. Indication under review: for use in combination with trastuzumab and chemotherapy in the adjuvant treatment of adult patients with HER2-positive early breastcancer at high risk of recurrence. The addition of pertuzumab to trastuzumab and chemotherapy improved invasive disease- free survival in patients with HER2-positive early breastcancer at high risk of recurrence. Overall survival data are immature. The submitting
Abemaciclib (Verzenio) - treatment of hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breastcancer Search Page - Drug and Health Product Register Language selection Search and menus Search Search website Search Topics menu You are here: Summary Basis of Decision - - Health Canada Expand all Summary Basis of Decision (SBD) for Contact: Summary Basis of Decision (SBD) documents provide information related to the original
Quantitative Image Analysis of HER2 IHC for BreastCancer CAP Laboratory Improvement Programs Quantitative Image Analysis of Human Epidermal Growth Factor Receptor 2 Immunohistochemistry for BreastCancer Guideline From the College of American Pathologists Marilyn M. Bui, MD, PhD; Michael W. Riben, MD; Kimberly H. Allison, MD; Elizabeth Chlipala, BS, HTL(ASCP)QIHC; Carol Colasacco, MLIS, SCT(ASCP); Andrea G. Kahn, MD; Christina Lacchetti, MHSc; Anant Madabhushi, PhD; Liron Pantanowitz, MD (...) (IHC) for breastcancer where QIA is used. Design.—The College of American Pathologists (CAP) convened a panel of pathologists, histotechnologists, and computer scientists with expertise in image analysis, immunohistochemistry, quality management, and breast pathology to develop recommendations for QIA of HER2 IHC in breastcancer. A systematic review of the literature was conducted to address 5 key questions. Final recom- mendations were derived from strength of evidence, open comment feedback
Type and timing of menopausal hormone therapy and breastcancer risk: individual participant meta-analysis of the worldwide epidemiological evidence. Published findings on breastcancer risk associated with different types of menopausal hormone therapy (MHT) are inconsistent, with limited information on long-term effects. We bring together the epidemiological evidence, published and unpublished, on these associations, and review the relevant randomised evidence.Principal analyses used (...) never users.During prospective follow-up, 108 647 postmenopausal women developed breastcancer at mean age 65 years (SD 7); 55 575 (51%) had used MHT. Among women with complete information, mean MHT duration was 10 years (SD 6) in current users and 7 years (SD 6) in past users, and mean age was 50 years (SD 5) at menopause and 50 years (SD 6) at starting MHT. Every MHT type, except vaginal oestrogens, was associated with excess breastcancer risks, which increased steadily with duration of use
Prophylactic antibiotics to prevent surgical site infection after breastcancer surgery. Surgery has been used as part of breastcancer treatment for centuries; however any surgical procedure has the potential risk of infection. Infection rates for surgical treatment of breastcancer are documented at between 3% and 15%, higher than average for a clean surgical procedure. Pre- and perioperative antibiotics have been found to be useful in lowering infection rates in other surgical groups, yet (...) there is no consensus on the use of prophylactic antibiotics for breastcancer surgery. This is an update of a Cochrane Review first published in 2005 and last updated in 2014.To determine the effects of prophylactic (pre- or perioperative) antibiotics on the incidence of surgical site infection (SSI) after breastcancer surgery.For this fourth update, in August 2018 we searched the Cochrane Wounds Specialised Register; the Cochrane Central Register of Controlled Trials (CENTRAL); Ovid MEDLINE (including In-Process
Medication Use to Reduce Risk of BreastCancer: US Preventive Services Task Force Recommendation Statement. Breastcancer is the most common nonskin cancer among women in the United States and the second leading cause of cancer death. The median age at diagnosis is 62 years, and an estimated 1 in 8 women will develop breastcancer at some point in their lifetime. African American women are more likely to die of breastcancer compared with women of other races.To update the 2013 US Preventive (...) Services Task Force (USPSTF) recommendation on medications for risk reduction of primary breast cancer.The USPSTF reviewed evidence on the accuracy of risk assessment methods to identify women who could benefit from risk-reducing medications for breastcancer, as well as evidence on the effectiveness, adverse effects, and subgroup variations of these medications. The USPSTF reviewed evidence from randomized trials, observational studies, and diagnostic accuracy studies of risk stratification models
Medication Use for the Risk Reduction of Primary BreastCancer in Women: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force. Medications to reduce risk of breastcancer are effective for women at increased risk but also cause adverse effects.To update the 2013 US Preventive Services Task Force systematic review on medications to reduce risk of primary (first diagnosis) invasive breastcancer in women.Cochrane Central Register of Controlled Trials (...) and Database of Systematic Reviews, EMBASE, and MEDLINE (January 1, 2013, to February 1, 2019); manual review of reference lists.Discriminatory accuracy studies of breastcancer risk assessment methods; randomized clinical trials of tamoxifen, raloxifene, and aromatase inhibitors for primary breastcancer prevention; studies of medication adverse effects.Investigators abstracted data on methods, participant characteristics, eligibility criteria, outcome ascertainment, and follow-up. Results of individual
Taxanes for adjuvant treatment of early breastcancer. Adjuvant chemotherapy improves survival in premenopausal and postmenopausal women with early breastcancer. Taxanes are highly active chemotherapy agents used in metastatic breastcancer. Review authors examined their role in early breastcancer. This review is an update of a Cochrane Review first published in 2007.To assess the effects of taxane-containing adjuvant chemotherapy regimens for treatment of women with operable early breast (...) cancer.For this review update, we searched the Specialised Register of the Cochrane BreastCancer Group, MEDLINE, Embase, CENTRAL (2018, Issue 6), the WHO International Clinical Trials Registry Platform (ICTRP), and ClinicalTrials.gov on 16 July 2018, using key words such as 'early breastcancer' and 'taxanes'. We screened reference lists of other related literature reviews and articles, contacted trial authors, and applied no language restrictions.Randomised trials comparing taxane-containing regimens
Whole breast irradiation with supraclavicular fossa radiotherapy and axillary radiotherapy for people with early breastcancer following a macrometastatic sentinel node biopsy Axillary radiotherapy - Health Technology Wales > Axillary radiotherapy Axillary radiotherapy Topic Status Complete Whole breast irradiation with supraclavicular fossa radiotherapy and axillary radiotherapy for people with early breastcancer following a macrometastatic sentinel node biopsy. Summary This report (...) was prepared by Health Technology Wales and Cedar (Cardiff & Vale University Health Board) on behalf of Velindre Cancer Centre. It summarises the existing evidence on the technology of interest to support a prioritisation discussion related to the implementation of radiotherapy procedures/techniques at Velindre Cancer Centre. Topic Exploration Report TER030 (03.2019) TER Access our guidance Our advice documents are free to download, but we would be grateful if you could help us improve our services
Internal mammary node irradiation for people with high-risk early breastcancer Internal mammary node irradiation - Health Technology Wales > Internal mammary node irradiation Internal mammary node irradiation Topic Status Complete Internal mammary node irradiation for people with high-risk early breastcancer. Summary This report was prepared by Health Technology Wales and Cedar (Cardiff & Vale University Health Board) on behalf of Velindre Cancer Centre. It summarises the existing evidence (...) on the technology of interest to support a prioritisation discussion related to the implementation of radiotherapy procedures/techniques at Velindre Cancer Centre. Topic Exploration Report TER031 (03.2019) TER Access our guidance Our advice documents are free to download, but we would be grateful if you could help us improve our services by telling us why you are looking at our advice and how you intend to use it. Full Name Job Title Organisation Email I'm looking at this document because We may like to contact
Partial breast irradiation for people with early breastcancer Partial breast irradiation - Health Technology Wales > Partial breast irradiation Partial breast irradiation Topic Status Complete Partial breast irradiation for people with early breastcancer. Summary This report was prepared by Health Technology Wales and Cedar (Cardiff & Vale University Health Board) on behalf of Velindre Cancer Centre. It summarises the existing evidence on the technology of interest to support a prioritisation (...) discussion related to the implementation of radiotherapy procedures/techniques at Velindre Cancer Centre. Topic Exploration Report TER029 (03.2019) TER Access our guidance Our advice documents are free to download, but we would be grateful if you could help us improve our services by telling us why you are looking at our advice and how you intend to use it. Full Name Job Title Organisation Email I'm looking at this document because We may like to contact you by email to find out more about how you used
BreastCancer: Medication Use to Reduce Risk Final Recommendation Statement: BreastCancer: Medication Use to Reduce Risk - US Preventive Services Task Force Search USPSTF Website Text size: Assembly version: 22.214.171.1248 Last Build: 5/9/2019 1:01:08 PM You are here: Final Recommendation Statement : Final Recommendation Statement Final Recommendation Statement BreastCancer: Medication Use to Reduce Risk Recommendations made by the USPSTF are independent of the U.S. government. They should (...) not be construed as an official position of the Agency for Healthcare Research and Quality or the U.S. Department of Health and Human Services. Recommendation Summary Population Recommendation Grade Women at increased risk for breastcancer The USPSTF recommends that clinicians offer to prescribe risk-reducing medications, such as tamoxifen, raloxifene, or aromatase inhibitors, to women who are at increased risk for breastcancer and at low risk for adverse medication effects. Women not at increased risk
Clinical utility of genomic signatures in early-stage breastcancer INAHTA Brief Issue 2019 Title Clinical utility of genomic signatures in early-stage breastcancer Agency HAS, French National Authority for Health (Haute Autorité de santé) 5 avenue du Stade de France – F 93218 La Plaine Cedex, France Tel: +33 (0)1 55 93 70 00, contact.seap@has-santé.fr, www.has-sante.fr Reference ISBN number 978-2-11-152376-0, link to full report https://www.has-sante.fr/portail/jcms/c_2748998/fr/utilite (...) aids for the prescribing of adjuvant chemotherapy (ACT) in certain cases of early breastcancer. Conclusions and results The HAS report concludes that GS are not intended to replace standard clinicopathological criteria (SCPC), which are considered to play a crucial role in the prescribing of ACT for early breastcancer. In light of inadequate 2 and/or lack of clinical data respectively found in first and second generation tests, the HAS considers it to be premature to recommend routine use of GS
Role of Patient and Disease Factors in Adjuvant Systemic Therapy Decision-Making for Early-Stage, Operable BreastCancer Role of Patient and Disease Factors in Adjuvant Systemic Therapy Decision Making for Early-Stage, Operable BreastCancer: Update of the ASCO Endorsement of the Cancer Care Ontario Guideline | Journal of Clinical Oncology Search in: Menu Article Tools ASCO SPECIAL ARTICLES Article Tools OPTIONS & TOOLS COMPANION ARTICLES No companion articles ARTICLE CITATION DOI: 10.1200/JCO (...) .19.00948 Journal of Clinical Oncology - published online before print June 17, 2019 PMID: Role of Patient and Disease Factors in Adjuvant Systemic Therapy Decision Making for Early-Stage, Operable BreastCancer: Update of the ASCO Endorsement of the Cancer Care Ontario Guideline , MD, PhD 1 x N. Lynn Henry ; , PhD 2 x Mark R. Somerfield ; , MD 3 x Vandana G. Abramson ; , MD 2 x Nofisat Ismaila ; , MD 4 x Kimberly H. Allison ; , MD 5 x Carey K. Anders ; , MS, MFA 6 x Diana T. Chingos ; , MD 7 x Andrea